Human Recombinant Insulin Market

Human Recombinant Insulin Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

Recombinant human insulin replaces animal-derived and semisynthetic insulin products enabling a reliable supply of insulin across the world at a reasonable cost.

The presence of a diverse range of products and availability along with discounts and offers on the online portals is expected to help the growth of the recombinant human insulin market in coming years.

Higher diabetes rates and a growing elderly population, North America held the biggest market share of the global human insulin market. The traditional North America human insulin medication market is expected to grow throughout the forecast period due to the affordability of human insulin products.

The human recombinant insulin market size was estimated to be US$ 32 billion in 2021.

The human recombinant insulin market is expected to witness a compound annual growth rate of 7.2% from 2023 to 2032.

Top players in the global recombinant human insulin market are Biocon, Bioton S.A., Eli Lilly and Company, Dongbao Enterprise Group Co Ltd., Novo Nordisk A/S, Gan & Lee Pharmaceuticals, Ltd., Julphar Gulf Pharmaceutical Industries, Sanofi S.A., Wanbang Biopharmaceuticals Co Ltd., and Zhuhai United Laboratories Co Ltd.